Top
image credit: Adobe Stock

AbbVie claims key approval for Vraylar in depression

December 19, 2022

Category:

The approval makes Vraylar (cariprazine) the ” first and only” dopamine and serotonin partial agonist indicated as an add-on therapy for depression, according to AbbVie, adding to the lengthening list of therapies for patients who struggle to control mood with standard antidepressants alone.

The new indication is a lynchpin of AbbVie’s plan to grow Vraylar into a $4 billion product, a sizeable increase from the $1.7 billion it achieved last year. After a slow start, the drug has emerged as the star of AbbVie’s $63 billion mega-merger with Allergan, which originally developed the drug with Gedeon Richter.

Read More on Pharmaphorum